Photo of Keith R. Solomon,  PhD

Keith R. Solomon, PhD

Boston Children's Hospital

Boston Children's Hospital
Phone: (617) 919-2639
Fax: (617) 730-0238


keith.solomon@childrens.harvard.edu

Keith R. Solomon, PhD

Boston Children's Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Orthopaedic Surgery, Harvard Medical School
  • Research Associate, Urology, Boston Children's Hospital
  • Administrative Director, Proteomics Center, Boston Children's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

The focus of my research is on the molecular mechanisms behind cholesterol’s role in the progression of prostate cancer. My laboratory and colleagues have been responsible for a number of pioneering reports demonstrating how cholesterol contributes to the regulation of Akt, a kinase that is known to play a role in prostate cancer progression, the neuroendocrine differentiation of prostate cancer cells, and the formation and regulation of cholesterol-enriched lipid rafts in many cell types including prostate cancer cells. We have also shown how hypercholesterolemia accelerates the growth of prostatic tumors, while hypocholesterolemia has the opposite effect and reduces tumor growth. Recently, we have developed preliminary studies suggesting that the intratumoral de novo synthesis of androgen from cholesterol is a critical factor driving tumor growth, and likely explains some or all of the growth promoting effects of hypercholesterolemia on prostatic tumors. Ongoing research involves investigating the association between cholesterol, CYP17A expression and prostate cancer progression, including whether pharmacologic cholesterol lowering affects the occurrence or severity of prostate cancer. Other ongoing work is to investigate the role of cholesterol in promoting breast cancer progression.

Publications

Powered by Harvard Catalyst
  • Pelton K, Coticchia CM, Curatolo AS, Schaffner CP, Zurakowski D, Solomon KR, Moses MA. Hypercholesterolemia Induces Angiogenesis and Accelerates Growth of Breast Tumors in Vivo. Am J Pathol 2014; 184:2099-110. PubMed
  • Solomon KR, Allott EH, Freeman MR, Freedland SJ. Re: Dysregulation of Cholesterol Homeostasis in Human Prostate Cancer Through Loss of ABCA1. Eur Urol 2013; 63:1128-9. PubMed
  • Freeman MR, Solomon KR. Statin Drugs and Prostate Cancer: Time to Consider Proactive Strategies in Patients. J Urol 2013. PubMed
  • Hager MH, Morley S, Bielenberg DR, Gao S, Morello M, Holcomb IN, Liu W, Mouneimne G, Demichelis F, Kim J, Solomon KR, Adam RM, Isaacs WB, Higgs HN, Vessella RL, Di Vizio D, Freeman MR. DIAPH3 governs the cellular transition to the amoeboid tumour phenotype. EMBO Mol Med 2012; 4:743-60. PubMed
  • Pelton K, Freeman MR, Solomon KR. Cholesterol and prostate cancer. Curr Opin Pharmacol 2012. PubMed
  • Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PLoS ONE 2012; 7:e30062. PubMed
  • Kim J, Di Vizio D, Kim TK, Kim J, Kim M, Pelton K, Clinton SK, Hai T, Hwang D, Solomon KR, Freeman MR. The response of the prostate to circulating cholesterol: activating transcription factor 3 (ATF3) as a prominent node in a cholesterol-sensing network. PLoS ONE 2012; 7:e39448. PubMed
  • Solomon KR, Freeman MR. The complex interplay between cholesterol and prostate malignancy. Urol Clin North Am 2011; 38:243-59. PubMed
  • Pelton K, Di Vizio D, Insabato L, Schaffner CP, Freeman MR, Solomon KR. Ezetimibe reduces enlarged prostate in an animal model of benign prostatic hyperplasia. J Urol 2010; 184:1555-9. PubMed
  • Di Vizio D,Solomon KR,Freeman MR. Cholesterol and cholesterol-rich membranes in prostate cancer: an update. Tumori 2008; 94:633-9. PubMed
  • Hager MH, Solomon KR, Freeman MR. The role of cholesterol in prostate cancer. Curr Opin Clin Nutr Metab Care 2006; 9:379-85. PubMed
  • Zhuang L, Kim J, Adam RM, Solomon KR, Freeman MR. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. J Clin Invest 2005; 115:959-68. PubMed
  • Kim J, Adam RM, Solomon KR, Freeman MR. Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells. Endocrinology 2003; 145:613-9. PubMed
  • Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem 2003; 91:54-69. PubMed
  • Zhuang L, Lin J, Lu ML, Solomon KR, Freeman MR. Cholesterol-rich lipid rafts mediate akt-regulated survival in prostate cancer cells. Cancer Res 2002; 62:2227-31. PubMed
  • Freeman MR, Solomon KR. Cholesterol and benign prostate disease. Differentiation 2011; 82:244-52. PubMed
Hide